Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 6/20 | 0.49 |
| ▸ | MAOA | P21397 | 5/20 | 0.49 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.49 |
| ▸ | SDHA | P31040 | 2/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | CALML3 | P27482 | 1/20 | 0.49 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.47 |
| ▸ | F10 | P00742 | 4/20 | 0.46 |
| ▸ | TOP2B | Q02880 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3207363 | 1.00 | MAOB (0.49) | MAOBMAOAPTGS1SDHALMNA | |
| SCHEMBL3195624 | 1.00 | MAOB (0.49) | MAOBMAOAPTGS1SDHALMNA | |
| SCHEMBL3195620 | 1.00 | MAOB (0.49) | MAOBMAOAPTGS1SDHALMNA | |
| SCHEMBL3202397 | 0.92 | MAOB (0.55) | MAOBMAOAPTGS1SDHALMNA | |
| SCHEMBL3205854 | 0.92 | MAOB (0.55) | MAOBMAOAPTGS1SDHALMNA | |
| SCHEMBL3193980 | 0.87 | CHRM1 (0.52) | MAOBMAOAPTGS1SDHALMNA | |
| SCHEMBL3196643 | 0.87 | CHRM1 (0.52) | MAOBMAOAPTGS1SDHALMNA | |
| SCHEMBL3209760 | 0.86 | CHRM1 (0.49) | MAOBMAOAPTGS1SDHALMNA | |
| SCHEMBL3209762 | 0.86 | CHRM1 (0.49) | MAOBMAOAPTGS1SDHALMNA | |
| SCHEMBL3431898 | 0.85 | MAOA (0.50) | MAOBMAOAPTGS1SDHALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2254892-B1 | BICYCLIC NITROIMIDAZOLES COVALENTLY LINKED TO SUBSTITUTED PHENYL OXAZOLIDINONES | GLOBAL ALLIANCE FOR TB DRUG DEV (US) | 2014-04-23 | — | — | EP | disclosed |
| US-7666864-B2 | Bicyclic nitroimidazole-substituted phenyl oxazolidinones | GLOBAL ALLIANCE FOR TB DRUG DEVELOPMENT (US) | 2010-02-23 | — | — | US | disclosed |
| US-20090281088-A1 | BICYCLIC NITROIMIDAZOLE-SUBSTITUTED PHENYL OXAZOLIDINONES | GLOBAL ALLIANCE FOR TB DRUG DEVELOPMENT (US) | 2009-11-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090281088-A1 | BICYCLIC NITROIMIDAZOLE-SUBSTITUTED PHENYL OXAZOLIDINONES | O60361, OXA1L, TBCD | MAOB 1703/4885MAOA 2050/4885PTGS1 1717/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.